Fresh Tracks Therapeutics Profit Margin

The latest profit margin for FRTX is -70.35% as of December 2023. That compares with -303.93% in the prior-year period — up 76.9% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Fresh Tracks Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, FRTX's profit margin moved from -303.93% to -70.35% — a 76.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Fresh Tracks Therapeutics's valuation or profitability profile.

Against Healthcare companies, FRTX currently prints -70.35% for profit margin, while the sector average sits near 14.34%. That is roughly 590.4% below the sector mean. Large gaps often invite a closer look at Fresh Tracks Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Fresh Tracks Therapeutics converts resources into returns. At -70.35%, FRTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -303.93% in the prior-year period — up 76.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting FRTX's profit margin (-70.35%), review year-over-year change from -303.93%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.